Angiotensin-(1-7) Treatment Early in Life Prevents Cardiac Hypertrophy in Adult Hypertensive Rats

J Cardiovasc Pharmacol. 2024 May 1;83(5):457-465. doi: 10.1097/FJC.0000000000001530.

Abstract

Angiotensin (Ang)-(1-7) is a cardioprotective peptide of the renin-angiotensin system. Prepuberty has been considered as a later susceptible window of development, and stressful factors in this life phase can induce chronic diseases in adulthood. We aimed to investigate whether the treatment with Ang-(1-7) during the prepuberty could attenuate the development of hypertension and cardiac injury in adult spontaneously hypertensive rats (SHRs). SHRs were treated with Ang-(1-7) (24 μg/kg/h) from age 4 to 7 weeks. Systolic blood pressure was measured by tail-cuff plethysmography up to 17th week. Thereafter, echocardiography was performed, and the rats were euthanized for the collection of tissues and blood. Ang-(1-7) did not change the systolic blood pressure but reduced the septal and posterior wall thickness, and cardiomyocyte hypertrophy and fibrosis in SHR. In addition, Ang-(1-7) reduced the gene expression of atrial natriuretic peptide and brain natriuretic peptide, increased the metalloproteinase 9 expression, and reduced the extracellular signal-regulated kinases 1/2 phosphorylation. Ang-(1-7) also prevented the reduction of Mas receptor but did not change the protein expression of angiotensin-converting enzyme, angiotensin-converting enzyme 2, AT1, and AT2. The treatment with Ang-(1-7) decreased the malondialdehyde (MDA) levels and increased superoxide dismutase-1 and catalase activities and protein expression of catalase. Our findings demonstrate that the treatment of SHR with Ang-(1-7) for 3 weeks early in life promotes beneficial effects in the heart later in life, even without altering blood pressure, through mechanisms involving the reduction of oxidative stress and ERK1/2 phosphorylation. In addition, this study supports the prepuberty as an important programming window.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Age Factors
  • Angiotensin I* / pharmacology
  • Animals
  • Antihypertensive Agents / pharmacology
  • Atrial Natriuretic Factor / metabolism
  • Blood Pressure* / drug effects
  • Cardiomegaly* / drug therapy
  • Cardiomegaly* / metabolism
  • Cardiomegaly* / pathology
  • Cardiomegaly* / physiopathology
  • Cardiomegaly* / prevention & control
  • Disease Models, Animal
  • Fibrosis
  • Hypertension* / drug therapy
  • Hypertension* / physiopathology
  • Hypertension* / prevention & control
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Natriuretic Peptide, Brain / metabolism
  • Oxidative Stress* / drug effects
  • Peptide Fragments* / pharmacology
  • Phosphorylation
  • Rats
  • Rats, Inbred SHR*
  • Ventricular Remodeling / drug effects

Substances

  • angiotensin I (1-7)
  • Angiotensin I
  • Peptide Fragments
  • Natriuretic Peptide, Brain
  • Matrix Metalloproteinase 9
  • Mmp9 protein, rat
  • Atrial Natriuretic Factor
  • Antihypertensive Agents